Palisade Bio Reports Positive Early Findings for PALI-2108
Initial cohorts of the study highlight the drug's safety and tolerability.
Carlsbad, CA -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical firm specializing in innovative treatments for autoimmune and inflammatory diseases, has released encouraging preliminary data from the initial three single ascending dose (SAD) cohorts involving PALI-2108, evaluated for the treatment of Ulcerative Colitis (UC).
The Phase 1 clinical trial is designed as a single-center, double-blind, placebo-controlled investigation focusing on the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PALI-2108 in healthy participants. Simultaneously, an open-label segment of the study includes patients diagnosed with UC.
So far, data indicate that PALI-2108, administered in varying doses of 15mg, 50mg, and 150mg to 24 subjects (with a 6:2 active to placebo ratio), has shown no treatment-related adverse events, serious adverse events, or laboratory abnormalities associated with the treatment. The preliminary pharmacokinetic analysis exhibits a delayed release profile that corresponds with the drug’s intended colonic bioactivation.
This early data establishes a hopeful foundation for subsequent phases. Palisade Bio plans to move forward with a crossover study aimed at understanding how food intake affects drug absorption, followed by multiple ascending dose (MAD) cohorts. Detailed safety evaluations will continue alongside pharmacokinetic assessments in these upcoming studies.
The primary goal of this Phase 1 trial is twofold: to assess the safety and tolerability in healthy individuals, and to gather data on how PALI-2108 behaves in UC patients. While several PDE4 inhibitors are already approved for certain inflammatory and fibrotic conditions, PALI-2108 stands out as a novel chemical entity, previously unadministered to humans.
Further insights will be obtained through biomarker assessments, including serum high sensitivity C-reactive protein (hsCRP) and fecal calprotectin (CalPro), and through histological evaluations of colon tissues. This comprehensive approach aims to shed light on PALI-2108’s action mechanism and efficacy, focusing on critical drug levels, PDE4 expression, and other pharmacodynamic markers.
Palisade aims to provide topline results from this clinical investigation in the near future, emphasizing its commitment to developing targeted therapies for chronic conditions.
For additional details about the clinical study, prospective participants may refer to clinicaltrials.gov under the identifier NCT06663605.
Understanding PALI-2108
PALI-2108 is distinguished as an orally administered, locally acting, colon-specific PDE4 inhibitor prodrug, specifically tailored for individuals suffering from Ulcerative Colitis. The data collected from ongoing studies is anticipated to bolster Palisade Bio’s precision medicine approach, which aims to identify responsive patient populations for future clinical evaluations.
About Palisade Bio
Palisade Bio is committed to progressing innovative biopharmaceutical solutions aimed at autoimmune, inflammatory, and fibrotic diseases. By focusing on targeted therapies, the company strives to reshape treatment options for patients facing these difficult health challenges.
Palisade's ongoing research highlights their dedication to advancing biomedical science and improving health outcomes for patients relying on cutting-edge medication. They invite the community to learn more about their mission and evolving projects by visiting their website.
Frequently Asked Questions
What is the significance of the Phase 1 trial for PALI-2108?
The Phase 1 trial assesses the safety and tolerability of PALI-2108, crucial for determining its viability for treating Ulcerative Colitis.
What were the initial findings regarding PALI-2108?
Initial findings suggest PALI-2108 is safe and well tolerated with no treatment-related adverse events reported in early cohorts.
How will the trial progress following these findings?
Palisade Bio plans to conduct crossover studies to evaluate food effects on pharmacokinetics, followed by additional cohort studies.
What are the next steps for Palisade Bio regarding PALI-2108?
The company intends to report topline data from the trial in the near future and continue advancing its clinical studies.
What role do biomarkers play in the research?
Biomarkers like hsCRP and fecal calprotectin will provide insights into PALI-2108's effects and the drug mechanisms involved.
